Clinical trials: Hepatitis C Recurrent
Liver Transplantation, Hepatitis C
Treatment of Recurrent Hepatitis C After Liver Transplantation
In France, 50% of the hepatitis C virus carriers develop chronic clinical hepatitis, which may lead to cirrhosis and liver transplantation. Transplant infection by hepatitis C virus is constant after transplantation.
- Trial name
- TRANSPEG (NCT00151580)
- Testing
- Ribavirin
- Where
- 16 sites in France
- Volunteers
- 200 people
- Sponsor
- Rennes University Hospital
Hepatitis C Virus Infection
Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men
Men who have sex with men (MSM) who cured from hepatitis C virus (HCV) infection are at substantial risk of HCV reinfection. In this study, the investigators aim to evaluate the effectiveness of an online behavioural…
- Trial name
- ICECREAM (NCT04156945)
- Testing
- Behavioural intervention, HCV RNA home-based test
- Where
- 15 sites in France, Netherlands
- Volunteers
- 258 people
- Sponsor
- Public Health Service of Amsterdam
Hepatitis C, Relapse
Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse
The primary goal of hepatitis C virus (HCV) Direct Acting Antivirals (DAAs) is to achieve undetectable HCV RNA in the blood. A response that should be maintained for at least 12 weeks from completion of therapy.
- Conditions
- Hepatitis C, Relapse, Antivirals
- Trial name
- NCT04662138
- Testing
- directly acting antivirals
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Hepatitis C, Chronic
A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation
The purpose of the study is to evaluate effect of steady-state (when the amount of drug administered (in a given time period is equal to the amount of drug eliminated in that same period) of simeprevir and daclatasvir on the…
- Trial name
- NCT01938625
- Testing
- Simeprevir, Daclatasvir, Ribavirin
- Where
- 6 sites in Germany, Poland and 1 more
- Volunteers
- 35 people
- Sponsor
- Janssen R&D Ireland
Hepatitis C
Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant
The aim of the study is to assess whether patients with recurrent hepatitis C after liver transplantation will benefit from a treatment with ribavirin/PEG-IFN-alpha combined treatment for 48 weeks.
- Trial name
- NCT00466219
- Testing
- Ribavirin, Pegylated interferon alpha2a
- Volunteers
- 25 people
- Sponsor
- University Hospital, Geneva
Hepatic Neoplasm Malignant Recurrent
Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC
The purpose of this study is to verify the superiority of NIK-333 (Peretinoin) to placebo in inhibiting the recurrence of HCV-positive HCC in patients showing complete cure of the disease, with the recurrence-free survival as the…
- Trial name
- NCT01640808
- Testing
- NIK-333(peretinoin)
- Where
- 66 sites in Japan
- Volunteers
- 616 people
- Sponsor
- Kowa Company, Ltd.
Hepatitis C
Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)
Different immunosuppressive drugs used in transplantation may reduce the body's defences against infection differently. It is known that patients with Hepatitis C virus, known as HCV, who switched from azathioprine to…
- Trial name
- NCT01134952
- Testing
- Mycophenolate to sirolimus switch
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- London Health Sciences Centre
Recurrent Hepatitis C
Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection
This study will assess the efficacy of everolimus as an inhibitor of fibrosis progression in liver transplant patients who have a recurrence of hepatitis C viral infection in the transplant
- Trial name
- REVERT (NCT00582738)
- Testing
- CsA-TAC (standard Treatment), Everolimus
- Where
- Argentina
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma, Hepatitis C Virus Infection
Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
We conducted a randomized controlled trial of adjuvant interferon (IFN) therapy in patients with hepatitis-C virus (HCV)-related cirrhosis who underwent curative resection of hepatocellular carcinoma (HCC) to investigate whether…
- Conditions
- Hepatocellular Carcinoma, Hepatitis C Virus Infection, Liver Cirrhosis, Interferon Treatment
- Trial name
- NCT00273247
- Testing
- Interferon alpha-2b
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute, Milan
Hepatitis C
Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
The purpose of this study is to learn if pre-liver transplant treatment, using peginterferon plus ribavirin, will clear hepatitis C virus (HCV) RNA from the blood in HCV-infected recipients and reduce the risk of recurrent HCV…
- Trial name
- LADR (NCT00135798)
- Testing
- LADR Treatment
- Where
- 8 sites in United States
- Volunteers
- 79 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Transplantation
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
The study aimed to present our experience in treating recurrent HCV genotype 4 infection post living donor liver transplantation (LDLT) since introduction of the second generation direct acting antiviral drugs (DAAs) in Egypt.
- Trial name
- NCT03133065
- Testing
- treatment of HCV with oral direct acting antiviral therapy
- Volunteers
- 89 people
- Sponsor
- Ain Shams University
Hepatitis C, Hepatocellular Carcinoma
Direct Acting Antiviral-Post Authorization Safety Study
This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting…
- Trial name
- NCT03707080
- Where
- 62 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Target PharmaSolutions, Inc.
Hepatitis C Virus
Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation
The purpose of this study is to learn about how different immunosuppressant therapies impact on recurrent hepatitis C virus infection in the new liver after liver transplant.
- Trial name
- NCT00710801
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Alberta
Hepatitis C, Medication Adherence
Patient-Centered Models of HCV Care for People Who Inject Drugs
People who inject drugs (PWID) have higher rates of hepatitis C virus (HCV) than do other groups. Effective, safe new treatments called direct-acting antiviral agents (DAAs) have been developed recently.
- Trial name
- HERO (NCT02824640)
- Testing
- Patient Navigation, modified Directly Observed Therapy
- Where
- United States
- Volunteers
- 755 people
- Sponsor
- Prisma Health-Upstate
Hepatitis C, Chronic
Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings
SHARP-C is an observational cohort study investigating the effect of direct-acting antiviral (DAA) therapy and reinfection in people with chronic hepatitis C virus (HCV) and recent injecting drug use.
- Trial name
- SHARP-C (NCT03343925)
- Where
- 4 sites in Australia
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Complication of Transplanted Liver, Hepatitis C, Chronic
Prediction of Hepatitis C Recurrence in Liver Transplant Recipients
The purpose of the study is to look at cells of the immune system to see if the cells are different among people with different risk factors that have received a liver transplant.
- Trial name
- NCT00867243
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northwestern University
Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of
HCV Reinfection in HD Patients Achieving SVR
Among the hemodialysis units, the global incidence of HCV infection ranges from 1.2% to 2.9%. Data regarding the long-term risk of reinfection among hemodialysis patients achieving SVR are limited.
- Conditions
- Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Hemodialysis Complication
- Trial name
- NCT04732832
- Where
- 7 sites in Taiwan
- Volunteers
- 350 people
- Sponsor
- National Taiwan University Hospital
Chronic Hepatitis C, Genotype 1
Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers
This is a non-randomized, open-label study examining the safety and efficacy of betaine in addition to standard anti-viral therapy in genotype 1 hepatitis C non-responders or relapsers to previous pegylated interferon plus…
- Conditions
- Chronic Hepatitis C, Genotype 1, Relapse
- Trial name
- NCT00882193
- Testing
- Betaine, Peginterferon alpha 2a, Ribavirin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Nebraska
Cirrhosis, Hepatitis B Infection
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
This phase I trial studies the side effects and the best dose of navitoclax when given together with sorafenib tosylate in treating patients with solid tumors that have returned (relapsed) or do not respond to treatment…
- Conditions
- Cirrhosis, Hepatitis B Infection, Hepatitis C Infection, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT02143401
- Testing
- Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study
- Where
- 10 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Hepatitis C Recurrence
A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation
Recurrence of Hepatitis C virus infection (HCV) is universal after orthotopic liver transplantation (LTx) and is associated with allograft failure, death and need for re-transplantation.
- Trial name
- NCT01074203
- Testing
- Nitazoxanide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic